Screener
Citius Oncology, Inc. CTOR Income Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $1.49M— | $1.67M— | $3.94M— | —— | —— | ||
| $491.84K— | $328.88K— | $789.21K— | —— | —— | ||
| $1M— | $1.34M— | $3.15M— | —— | —— | ||
| 67.1%— | 80.3%— | 80%— | —— | —— | ||
| $218.5K-76.7% | $1.08M-65.6% | $1.02M-19.5% | $1.08M-17.0% | $938.28K-17.1% | ||
| $4.22M+124% | $23.63M+953% | $2.86M-13.9% | $1.34M-63.9% | $1.88M+22.1% | ||
| $9.72M+96.5% | $29.95M+301% | $8.41M+31.5% | $4.71M-29.4% | $4.94M+6.8% | ||
| -$8.72M-76.3% | -$28.61M-283% | -$5.25M+17.9% | -$4.71M+29.4% | -$4.94M-6.8% | ||
| -583.5%— | -1,716.2%— | -133.2%— | —— | —— | ||
| $231.73K+44.2% | $33.03K— | $45.84K— | $57.28K— | $160.76K— | ||
| -$314.38K-95.6% | $1.77M— | -$17.55K— | -$20.9K-101% | -$160.76K-125% | ||
| -$9.03M-76.9% | -$26.84M-259% | -$5.27M+17.6% | -$4.73M+29.0% | -$5.11M-10.3% | ||
| -$107.35K-141% | -$231.21K-188% | $264.24K0.0% | $264.24K+83.5% | $264.24K+83.5% | ||
| -$8.92M-66.2% | -$26.61M-244% | -$5.53M+16.9% | -$5M+26.7% | -$5.37M-12.5% | ||
| -597.4%— | -1,596%— | -140.3%— | —— | —— | ||
| -$0.080.0% | -$0.27-145% | -$0.06+33.3% | -$0.06+40.0% | -$0.08-14.3% | ||
| -$8.72M-76.3% | -$28.61M-283% | -$5.25M+17.9% | -$4.71M+29.4% | -$4.94M-6.8% |
FAQ
- Is Citius Oncology, Inc. profitable?
- Citius Oncology, Inc. is not currently profitable: it reported a net loss of $46.1M over the trailing twelve months.
- What is Citius Oncology, Inc.'s earnings per share?
- Citius Oncology, Inc.'s diluted EPS over the trailing twelve months is $-0.47.
- Where does Citius Oncology, Inc.'s income statement data come from?
- Every line is extracted from Citius Oncology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.